Poland· PL-100353391
Teysuno
A tegafur, kombinationen product containing tegafurum + gimeracilum + oteracilum, registered in Poland by Nordic Group B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tegafur, kombinationen is registered in 9 of 19 countries.
Countries holding a registration under ATC L01BC53 (tegafur, kombinationen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Tegafur, kombinationen · ATC L01BC53
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Tegafurum + Gimeracilum + Oteracilum
- Manufacturer
- Nordic Group B.V.
- Country
- Poland (PL)
- ATC code
- L01BC53
- ATC class
- Tegafur, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tegafur, kombinationen in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTEYSUNONordic Group BV, Hoofddorp
- SpainTEYSUNO 15 mg/4,35 mg/11,8 mg CAPSULAS DURASNordic Group B.V.
- United KingdomTeysuno 15mg/4.35mg/11.8mg capsulesNordic Pharma Ltd
- IrelandTeysuno 15 mg/4.35 mg/11.8 mg hard capsulesNordic Group B.V.
- IcelandTeysunoNordic Group BV
- NetherlandsTeysuno 15 mg/4,35 mg/11,8 mg harde capsulesNordic Group BV
- NorwayTeysunoNordic Group BV
- SwedenTeysuno 15 mg/4,35 mg/11,8 mg Kapsel, hårdNordic Group BV
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Teysuno
- Iceland · Teysuno
- Liechtenstein · Teysuno
- Norway · Teysuno
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/16088093-5f5f-47ee-b930-ccb2fb6601e7 GET /v1/drugs/16088093-5f5f-47ee-b930-ccb2fb6601e7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "20 mg + 5,8 mg + 15,8 mg",
"packaging": "Rpz ¦ EU/1/11/669/003 ¦ 110776\n42 kaps.\nRpz ¦ EU/1/11/669/004 ¦ 110777\n84 kaps.",
"substance": "Tegafurum 20 mg + Gimeracilum 5.8 mg + Oteracilum 15.8 mg",
"common_name": "Tegafurum + Gimeracilum + Oteracilum",
"pl_product_id": "100353391",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tegafur, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.